Last reviewed · How we verify
rhu-pGelsolin
At a glance
| Generic name | rhu-pGelsolin |
|---|---|
| Also known as | Recombinant plasma gelsolin, CBC-100, Solinex |
| Sponsor | Critical Biologics Corporation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Ascending Single Dose Study of Rhu-pGelsolin in Patients With Decreased Gelsolin Levels (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhu-pGelsolin CI brief — competitive landscape report
- rhu-pGelsolin updates RSS · CI watch RSS
- Critical Biologics Corporation portfolio CI